Ketamine for Bipolar Depression: Encouraging Evidence—and Questions That Still Matter

For someone living with bipolar depression, continuing to work and meet responsibilities can conceal how difficult daily life has become. When several treatments have failed to provide adequate relief, news of another option can carry considerable hope. That makes it especially important to explain emerging research with both optimism and precision.

A small randomized clinical trial published in JAMA Psychiatry on September 2, 2026, adds encouraging evidence for intravenous ketamine in treatment-resistant bipolar depression. Researchers randomized 68 adults with bipolar I or II disorder to four ketamine or midazolam infusions over two weeks. Participants had experienced at least two unsuccessful medication trials and continued a stable mood stabilizer or antipsychotic.

Among the 63 participants included in the efficacy analysis, depression scores at day 14 were approximately 7.3 points lower with ketamine than with midazolam on the Montgomery–Åsberg Depression Rating Scale. The randomized, double-blind design and active comparator strengthen the evidence for a short-term antidepressant effect.

The safety findings also require careful interpretation. Neither group experienced mania, hypomania, psychosis, or suicide attempts during the reported period; one participant in each group developed mixed features. However, a small, brief trial cannot exclude uncommon complications or establish long-term safety. Read the original study.

Several distinctions matter when translating this research into a treatment conversation.

First, the study evaluated ketamine as an addition to ongoing treatment. Its findings do not establish that ketamine can replace a mood stabilizer or antipsychotic. They also concern a specific intravenous protocol. They should not automatically be extended to every treatment marketed under the broad label of “ketamine therapy.”

Second, improvement over two weeks leaves longer-term questions unanswered. How durable is the benefit? What happens after the initial infusions stop? What maintenance approach offers the best balance of benefit, burden, and risk? This report does not settle those questions.

Third, symptom improvement is only part of what people want from treatment. For an adult balancing a career, relationships, and household responsibilities, meaningful recovery may include being more present with family, managing ordinary tasks with less difficulty, and having energy for life beyond work. Those are valuable goals to discuss and track, but we should not assume that a change on a depression scale proves those outcomes occurred.

My takeaway is that this study supports a more informed conversation about an additional treatment option for selected adults with difficult-to-treat bipolar depression. It provides a reason for measured hope while leaving room for careful patient selection, ongoing monitoring, and realistic expectations.

When discussing a promising treatment, we should ask both how much it helps and what we still need to learn about keeping people well.